Pulmonary toxicity assessment of tumor necrosis factor α inhibitors in the treatment of IBD: a real world study based on US food and drug administration adverse events reporting system (FAERS)
TNF-α inhibitors had the strongest signal of pulmonary toxicity relative to other control therapies. Golimumab had the strongest signal of pulmonary toxicity relative to other TNF-α inhibitors. When TNF-α inhibitors are used in the treatment of IBD, pulmonary-related AEs should be vigilant.
Authors
- Mengling Ouyang (ORCID: https://orcid.org/0009-0002-5244-8379)
- Yazheng Zhao (ORCID: https://orcid.org/0000-0002-5162-4812)
- Shupeng Zou (ORCID: https://orcid.org/0000-0003-3545-5411)
- Shanshan Sun (ORCID: https://orcid.org/0000-0002-6286-3114)
- Qian Cheng (ORCID: https://orcid.org/0000-0003-4012-8693)
- Xuan Shi (ORCID: https://orcid.org/0000-0002-6226-8833)
Institutions
- Minzu University of China (CN)
- Tongji Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2024-12-19
- DOI
- https://doi.org/10.1080/14740338.2024.2444580
- Citations
- 2
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 1.10